Symposium | How to sequence BCMA-directed therapies in RRMM

This independent educational activity was supported by GSK. All content was developed independently by the faculty. The funder was allowed no influence on the content of this activity.

At the European School of Haematology (ESH) 7th Translational Research Conference on Multiple Myeloma in 2024, the Multiple Myeloma Hub held a symposium titled: How to sequence B-cell maturation antigen (BCMA)-directed therapies in early relapsed/refractory multiple myeloma (RRMM). Mohamad Mohty chaired a panel discussion, focusing on the strategies for sequencing BCMA-directed therapies in RRMM, joined by expert speakers Martin Kaiser and Rakesh Popat.

In this panel discussion, Mohamad Mohty shared a case study of a 74-year-old female patient with RRMM, who experienced progression after five years of remission following treatment with isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd). This case prompted a discussion on the most effective and practical next-line treatments, considering the benefits and risks of options such as chimeric antigen receptor (CAR) T-cell therapy, bispecific antibodies, antibody-drug conjugates, and other novel combinations.

The panelists discussed treatment options for patients who have become refractory to existing therapies, optimal sequencing of BCMA-directed therapies, and toxicity profiles of each option. They also highlighted the challenge of treatment accessibility, particularly in lower-income countries, as well as the importance of aligning with patient preferences.